Skip to Main Content

Paper Details

Genetic Alterations in the PI3K/AKT Pathway and Baseline AKT Activity Define AKT Inhibitor Sensitivity in Breast Cancer Patient-derived Xenografts.
Clin Cancer Res
17
2020
AKT, AKT1, AKT1 p.E17K, AZD5363, Breast Cancer, Breast Cancer Patient-derived Xenografts, HER2, HER2-negative metastatic breast cancer, HER2-negative patient-derived xenografts, MTOR, PDX, PDXs, PI3K, PIK3CA, PTEN, Patient, S6K1, TSC1, capivasertib, cyclin D1, estrogen, estrogen receptor, estrogen receptor-positive breast cancer, fulvestrant, mTOR complex 1, mTORC1, p, p.E17K, pAKT S473, pS6 S235, paclitaxel, patient, patients, triple-negative metastatic breast cancer
Author NameAffiliation
Alejandra BrunaCancer Research UK Cambridge Institute, University of Cambridge
Gordon B MillsKnight Cancer Institute, Oregon Health and Sciences University
Gordon B MillsThe University of Texas MD Anderson Cancer Center
Gordon B MillsKnight Cancer Institute, Oregon Health and Sciences University
Gordon B MillsThe University of Texas MD Anderson Cancer Center
Carlos CaldasDepartment of Oncology and Cancer Research UK Cambridge Institute, University of Cambridge
Carlos CaldasNIHR Cambridge Biomedical Research Centre and Cambridge Experimental Cancer Medicine Centre at Cambridge University Hospitals NHS Foundation Trust
Rodrigo DienstmannVall d'Hebron Institute of Oncology
Barry R Davies
  • 1 - 9

Datasets

Release 1.2